Ligand Pharmaceuticals (LGND) Debt to Equity (2011 - 2026)

Ligand Pharmaceuticals' (LGND) quarterly Debt to Equity came in at $0.45 in Q1 2026, up 2.16% quarter-over-quarter from $0.44 in Q4 2025.

Ligand Pharmaceuticals (LGND) Debt to Equity (2011 - 2026) Analysis & Trends

Ligand Pharmaceuticals has disclosed Debt to Equity across 13 years of filings, most recently posting $0.45 for Q1 2026.

Debt to Equity for Q1 2026 came in at $0.45, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $0.45 (changed N/A YoY), and the FY2025 annual result was $0.44, changed N/A from the prior year.
Debt to Equity came in at $0.45 for Q1 2026 at Ligand Pharmaceuticals, up from $0.44 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $0.47 in Q3 2025 to a low of $0.09 in Q3 2022.
The 4-year median for Debt to Equity is $0.14 (2022), against an average of $0.26.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.32
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Ligand Pharmaceuticals	5.47 Bn	4.69 Bn	48.45 Mn	0.45

Download Data